NNMTi
Based on 12 publication(s) in Google Scholar
NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=1.2 μM) and selectively binds to the NNMT substrate-binding site residues. NNMTi promotes myoblast differentiation in vitro and enhances fusion and regenerative capacity of muscle stem cells (muSCs) in aged mice.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.70%
- CAS No.: 42464-96-0
- 화학식: C10H11IN2
- 분자량:286.11
-
보관:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) NNMTi
More- Mol Cancer. 2025 Mar 15;24(1):79. [Abstract]
- Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
- Gut. 2023 Dec 7;73(1):63-77. [Abstract]
- Genes Dis. 2026 May 27.
- Cell Commun Signal. 2025 Jul 21;23(1):348. [Abstract]
- Cell Death Discov. 2025 Oct 7;11(1):450. [Abstract]
- Oncogene. 2026 Aug;45(29):2959-2977. [Abstract]
- Aging Cell. 2024 Jun 5:e14236. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 2):115882. [Abstract]
- Toxicology. 2025 May:513:154084. [Abstract]
- J Diabetes Complications. 2025 Jan 18;39(2):108952. [Abstract]
- Physiol Rep. 2025 Oct;13(20):e70615. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
IHC
-
WB
-
WB
-
RT-PCR
Biological Activity
NNMTi (10-30 μM; 96 hours) produces a concentration-related increase in myoblast differentiation on C2C12 myoblast differentiation. 30 μM NNMTi results in 18% MHC-positive myotube nuclei, representing a 45% increase in the extent of myoblast differentiation compared to untreated differentiating myoblasts (12% MHC-positive myotube nuclei)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 42464-96-0
-
Appearance Solid
-
분자량 286.11
-
화학식 C10H11IN2
-
Color Brown to reddish brown
-
SMILES
C[N+]1=C2C=CC=C(N)C2=CC=C1.[I-]
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, sealed storage, away from moisture
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer. [Abstract]2025 Mar 15;24(1):79. PMID: 40089784
NNMTi purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 15;24(1):79. [Abstract]
NNMTi (10 mg/kg; i.p.; once daily) treatment effectivelyreversed EGR1 or ALDH3A1 overexpression-promoted tumor growth of BALB/c nude mice.
NNMTi purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 15;24(1):79. [Abstract]
NNMTi (10 mg/kg; i.p.; once daily) reversed the expression of Ki67 induced by the overexpression of EGR1 or ALDH3A1 in BALB/c nude mice.
NNMTi purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2025 Mar 15;24(1):79. [Abstract]
WB assays were performed following administration of NNMTi (10-40 mg/kg) to osimertinib-resistant cells (PC9/OR and HCC827/OR).
-
Cell Metab
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. [Abstract]2024 Jun 18:S1550-4131(24)00189-X. PMID: 38897198
NNMTi purchased from MedChemExpress. Usage Cited in: Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
NNMTi (10 μM; 48 h) reversed the upregulation of EMT markers (Vimentin and N-cadherin) in MFC induced by coculture with NNMT-overexpressing CAFs.
NNMTi purchased from MedChemExpress. Usage Cited in: Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
Expression of tumor-promoting markers (Vimentin, Vegfa, II10, and Tgfb1) in mouse subcutaneous tumor-isolated CAFs (m-CAFs) or Nnmt-overexpressing (oxNnmt) m-CAFs treated with NNMT inhibitor NNMTi (10 mM, 48 h) was detected by RT-qPCR.
-
Gut
NNMT enriches for AQP5+ cancer stem cells to drive malignant progression in early gastric cardia adenocarcinoma. [Abstract]2023 Dec 7;73(1):63-77. PMID: 36977555 -
-
Cell Commun Signal
NAMPT and NNMT released via extracellular vesicles and as soluble mediators are distinguished traits of BRAF inhibitor resistance of melanoma cells impacting on the tumor microenvironment. [Abstract]2025 Jul 21;23(1):348. PMID: 40691620 -
Cell Death Discov
Insufficient NNMT promotes autophagy and disrupts progesterone signaling in endometrial stromal cells in recurrent implantation failure by modulating the H3K9me3-ALDH1A3 pathway. [Abstract]2025 Oct 7;11(1):450. PMID: 41057307 -
Oncogene
Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment. [Abstract]2026 Aug;45(29):2959-2977. PMID: 42310095 -
Aging Cell
Identification of nicotinamide N-methyltransferase as a promising therapeutic target for sarcopenia. [Abstract]2024 Jun 5:e14236. PMID: 38838088 -
Int Immunopharmacol
Nicotinamide N-methyltransferase mediates redox regulation and colonic epithelial barrier impairment by SIRT1/PPAR-γ/NLRP6/NRF2 axis in inflammatory bowel disease. [Abstract]2026 Jan 1;168(Pt 2):115882. PMID: 41275826 -
Toxicology
NNMT is involved in deoxynivalenol-induced hepatocyte toxicity via promoting ferroptosis. [Abstract]2025 May:513:154084. PMID: 39983889 -
J Diabetes Complications
Nicotinamide n-methyltransferase inhibitor synergizes with sodium-glucose cotransporter 2 inhibitor to protect renal tubular epithelium in experimental models of type 2 diabetes mellitus. [Abstract]2025 Jan 18;39(2):108952. PMID: 39848127 -
Physiol Rep
Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease. [Abstract]2025 Oct;13(20):e70615. PMID: 41108586
용액&용해도
DMSO : 20.83 mg/mL (72.80 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 2.27 mg/mL (7.93 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Harshini Neelakantan, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019 May;163:481-492. [Content Brief]
[2]. Harshini Neelakantan, et al. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.4952 mL | 17.4758 mL | 34.9516 mL | 87.3790 mL |
| 5 mM | 0.6990 mL | 3.4952 mL | 6.9903 mL | 17.4758 mL | |
| DMSO | 10 mM | 0.3495 mL | 1.7476 mL | 3.4952 mL | 8.7379 mL |
| 15 mM | 0.2330 mL | 1.1651 mL | 2.3301 mL | 5.8253 mL | |
| 20 mM | 0.1748 mL | 0.8738 mL | 1.7476 mL | 4.3689 mL | |
| 25 mM | 0.1398 mL | 0.6990 mL | 1.3981 mL | 3.4952 mL | |
| 30 mM | 0.1165 mL | 0.5825 mL | 1.1651 mL | 2.9126 mL | |
| 40 mM | 0.0874 mL | 0.4369 mL | 0.8738 mL | 2.1845 mL | |
| 50 mM | 0.0699 mL | 0.3495 mL | 0.6990 mL | 1.7476 mL | |
| 60 mM | 0.0583 mL | 0.2913 mL | 0.5825 mL | 1.4563 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
NNMTi Related Classifications
HY-131042 Related Classifications
Powered by Bioz